替诺福韦和恩替卡韦对老年慢性乙肝患者的抗病毒临床疗效观察  

Clinical Efficacy Observation of Tenofovir and Entecovir in Elderly Patients with Chronic Hepatitis B

作　　者：熊玮[1] XIONG Wei(Department of Infection,Guizhou Space Hospital,Zunyi 563003,Guizhou Province,China)

机构地区：[1]贵州航天医院感染科,贵州遵义563003

出　　处：《罕少疾病杂志》2022年第6期76-77,101,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探讨替诺福韦和恩替卡韦在老年慢性乙肝患者中的应用价值。方法选择2018年6月至2020年6月我院收治的老年慢性乙肝患者102例,按随机数字表法分为两组,各51例。对照组采用恩替卡韦治疗,研究组采用替诺福韦治疗,连续用药36周。比较两组抗病毒临床疗效、乙型肝炎病毒(HBV)-DNA水平、炎症因子水平、不良反应。结果治疗12周后,研究组HBV-DNA阴转率、丙氨酸氨基转移酶(ALT)复常率高于对照组,差异有统计学意义(P<0.05);治疗36周后,两组HBV-DNA阴转率与ALT复常率相比,差异无统计学意义(P>0.05);治疗前,两组HBV-DNA、肿瘤坏死因子-α(TNF-α)、白介素-10(IL-10)水平相比,差异无统计学意义(P>0.05);治疗12周后,研究组HBV-DNA、TNF-α、IL-10水平低于对照组,差异有统计学意义(P<0.05);治疗36周后,两组HBV-DNA、TNF-α、IL-10水平相当,差异无统计学意义(P>0.05);两组不良反应相当,差异无统计学意义(P>0.05)。结论替诺福韦与恩替卡韦治疗老年慢性乙肝远期疗效相当,但替诺福韦抗病毒作用起效较早,可及时减轻机体炎症反应,且安全可靠。Objective To investigate the application value of tenofovir and entecovir in elderly patients with chronic hepatitis B.Methods 102 elderly chronic hepatitis B patients admitted in our hospital from June 2018 to June 2020,divided into two groups and 51 each according to randomized digital table.The control group was treated with entecovir and the study group with tenofovir for 36 weeks.Comparing the clinical efficacy of the two antiviral groups,hepatitis B virus(HBV)-DNA levels,inflammatory factor levels,and adverse reactions.Results After 12 weeks of treatment,HBVDNA and alanine aminotransferase(ALT)were higher than in the control group,and the difference was statistically significant(P<0.05).After 36 weeks of treatment,two groups of HBV-DNA negative conversion rate compared with the ALT conversion rate,Differences have no statistical significance(P>0.05);Before the treatment,Compared with the HBV-DNA,tumor necrosis factor-α(TNF-α)and inter L-10(IL-10)levels of two groups,and differences have no statistical significance(P>0.05).After twelve weeks of treatment,the HBV-DNA,TNF-α,IL-10 level was lower than the control group,and the difference was statistically significant(P<0.05).After 36 weeks of treatment,the two groups of HBV-DNA,TNF-α,IL-10 levels were comparable,and differences have no statistical significance(P>0.05).The two groups had comparable adverse reactions,and the difference are not statistically significant(P>0.05).Conclusion Tenofovir and entecovir treated elderly chronic hepatitis B,but tenofovir worked early to reduce inflammation and was safe and reliable.

关 键 词：老年慢性乙肝 替诺福韦 恩替卡韦 临床疗效 炎症因子 

分 类 号：R969.4[医药卫生—药理学]